Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 3/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645516 | 0.86 | DPP4 (0.41) | DPP4OPRM1OPRL1CTSLCTSB | |
| SCHEMBL30291457 | 0.86 | DPP4 (0.41) | DPP4OPRM1OPRL1CTSLCTSB | |
| SCHEMBL23645514 | 0.84 | DPP4 (0.39) | DPP4OPRM1OPRL1CTSLCTSB | |
| SCHEMBL23645210 | 0.83 | HDAC4 (0.41) | DPP4OPRM1OPRL1CTSLCTSB | |
| SCHEMBL30291278 | 0.83 | OPRM1 (0.39) | DPP4OPRM1OPRL1CTSLCTSB | |
| SCHEMBL23668821 | 0.83 | OPRM1 (0.39) | DPP4OPRM1OPRL1CTSLCTSB | |
| SCHEMBL23645698 | 0.81 | HDAC4 (0.43) | DPP4OPRM1OPRL1CTSLCTSB | |
| SCHEMBL23645697 | 0.79 | HDAC4 (0.39) | DPP4OPRM1OPRL1CTSLCTSB | |
| SCHEMBL23668788 | 0.76 | PPM1D (0.34) | ALOX15 | |
| SCHEMBL23380038 | 0.71 | DPP4 (0.49) | DPP4OPRM1OPRL1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087700-B | Spirocyclic tetrahydroquinazolines | 苏州亚盛药业有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021139748-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-15 | — | — | WO | disclosed |
| CN-113087700-A | Spirocyclic tetrahydroquinazolines | 苏州亚盛药业有限公司 | 2021-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | KRAS, NRAS, HRAS | DPP4 3662/4885OPRM1 2886/4885OPRL1 2634/4885 |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | KRAS, NRAS, HRAS | DPP4 3662/4885OPRM1 2886/4885OPRL1 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.